Cortisol as a Prognostic Marker of Short-Term Outcome in Chinese Patients with Acute Ischemic Stroke

Wen-Jie Zi, Jie Shuai*

Department of Neurology, Xin Qiao Hospital, Third Military Medical University, Chongqing, P. R. China

Introduction

In China, approximately 1.6 million stroke patients will die every year, which has exceeded heart disease to become the second leading cause of death and adult disability [1]. In addition, China has 2.5 million new stroke cases each year and 7.5 million stroke survivors [2]. Reliable prognostic markers available during the initial phase after acute stroke may aid clinical decision-making and allocation of healthcare resources.

Numerous clinical variables (e.g., advanced age and symptom severity) have been identified as potential predictors of outcome. However, the need to identify better biomarkers as predictors of outcome in acute stroke still exists. The period following ischemic stroke can be considered as a reaction to a stressful event. The major characteristic of the stress response is the activation of the sympathetic nervous system (SNS) and the hypothalamo–pituitary–adrenal (HPA) axis [3]. In cerebral ischemia, endocrine changes of the HPA axis are one of the first measurable alterations [4]. Cortisol is a HPA axis-related hormone with a robust circadian rhythm where levels typically peak in the morning hours and decline across the day [5].

Cortisol has an important effect on the glucose, protein and fat metabolism and cardiovascular reactivity [6]. Some studies showed that high cortisol level was associated with decreased physical function [7], level of consciousness [8]. Fiorentino et al [5] reported that saliva levels of cortisol can be seen as a useful biological marker for identification of patients who are “at risk” of lower benefits from inpatient rehabilitation services. In addition, increased concentrations of cortisol have been observed in subarachnoid haemorrhage [9], and acute ischemic stroke [4]. Some studies have found that elevated plasma or urinary cortisol concentrations in acute ischemic stroke are related to greater stroke severity, larger infarct volume and/or unfavorable outcome, including death [4,10–13]. For patients after acute ischemic stroke, high serum cortisol level was significantly correlated to the presence of acute confusional state [8]. We propose a hypothesis that higher levels of serum cortisol at admission could predict short-term outcomes in Chinese patients with acute ischemic stroke.

Abstract

Background: Early prediction of outcome is important for allocation of therapeutic strategies. Endocrine alterations of the hypothalamus–pituitary–axis are one of the first stress-induced alterations after cerebral ischemia. We therefore evaluated the prognostic value of serum cortisol in Chinese patients with an acute ischemic stroke.

Methods: In a prospective observational study, serum cortisol was measured using a solid-phase, competitive chemiluminescent enzyme immunoassay on admission in serum of 226 consecutive Chinese patients with an acute ischemic stroke. The prognostic value of serum cortisol to predict the functional outcome, mortality within 90 days, was compared with clinical variables (e.g., advanced age and the National Institutes of Health Stroke Scale [NIHSS] score) and with other known predictors.

Results: Patients with a poor outcome and nonsurvivors had significantly increased serum cortisol levels on admission (P < 0.0001, P < 0.0001). There was a positive correlation between levels of cortisol and the NIHSS (r = 0.298, P < 0.0001), glucose levels (r = 0.324, P < 0.0001) and infarct volume (r = 0.328, P < 0.0001). Cortisol was an independent prognostic marker of functional outcome and death [odds ratio 3.44 (2.58–6.23) and 4.21 (1.89–9.24), respectively, P < 0.0001 for both, adjusted for age, the NIHSS and other predictors] in patients with ischemic stroke. In receiver operating characteristic curve analysis, cortisol could improve the NIHSS score in predicting short-term functional outcome (Area under the curve [AUC] of the combined model, 0.87; 95% CI, 0.82–0.92; P = 0.01) and mortality (AUC of the combined model, 0.90; 95% CI, 0.84–0.95; P = 0.01).

Conclusion: Cortisol can be seen as an independent short-term prognostic marker of functional outcome and death in Chinese patients with acute ischemic stroke even after correcting confounding factors. Combined model can add significant additional predictive information to the clinical score of the NIHSS.

Citation: Zi W-J, Shuai J (2013) Cortisol as a Prognostic Marker of Short-Term Outcome in Chinese Patients with Acute Ischemic Stroke. PLoS ONE 8(9): e72758. doi:10.1371/journal.pone.0072758

Copyright: © 2013 Zi, Shuai. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: zhangbytianjin@163.com
stroke. The aim of this prospective cohort study was to verify this hypothesis.

**Subjects and Methods**

**Patients and Study Design**

We conducted a prospective cohort study at the neurology department of the General Hospital, Tianjin Medical University, China. From February 2009 to September 2012, all patients with first-ever acute ischemic stroke were included. All patients were Chinese. All patients were admitted within 48 hours of experiencing a new focal or global neurological event. Brain imaging (either CT or MRI) was performed routinely within 24 to 48 hours after admission. An acute ischemic stroke was defined according to the World Health Organization criteria [14]. We excluded patients with other causes of activation of the HPA axis (e.g., those with surgical procedures within the last 3 weeks or those with concomitant preexisting or nosocomial infections), intracranial hemorrhage, malignancy, febrile disorders, acute or chronic inflammatory disease at study enrollment. Patients receiving immunosuppressive agents, all types of steroids, and psychotropic drugs were also excluded.

One hundred healthy people matched for age and gender were assigned to the normal control group. Records of potential controls were reviewed by a neurologist (not an author) to exclude the presence of stroke, other types of diseases. Controls receiving immunosuppressive agents, all types of steroids, and psychotropic drugs also should be excluded. The Institutional Review Committee on Human Research of Tianjin Medical University approved the study protocol. The patients or their relatives gave written informed consent prior to entering the study.

**Clinical Variables**

At baseline, demographic data (age and sex) and history of conventional vascular risk factors (hypertension, diabetes mellitus, atrial fibrillation, hyperlipidemia, smoking habit, alcohol abuse) were obtained. All these information were obtained through interviews. Routine blood and biochemical tests, ECG, and a baseline brain CT/MRI scan were performed in all patients at admission. Stroke severity was assessed on admission using the National Institutes of Health Stroke Scale (NIHSS) by a neurologist [15]. The NIHSS score ranges from 0 to 34 and higher values reflect more severe neurological damage. Whenever the NIHSS values were missing, values were estimated from chart review retrospectively, previously shown to give reliable estimates for NIHSS [16]. Stroke subtype was classified according to TOAST (Trial of Org 10172 in Acute Stroke Treatment) criteria [17]. The clinical stroke syndrome was determined by applying the criteria of the Oxfordshire Community Stroke Project: total anterior circulation syndrome (TACS); partial anterior circulation syndrome (PACS); lacunar syndrome (LACS); and posterior circulation syndrome (POCS) [18].

**End Points and follow-up**

We also recorded time from symptom recognition to admission. We considered the following endpoints: (i) the primary end-point was functional outcome on day 90. Functional outcome was assessed by the modified Rankin Scale (mRS) [19]. A favourable functional outcome was defined as a mRS of 0–2 points, whereas an unfavourable outcome was defined as a mRS of 3–6 points; (ii) secondary end-points were all-cause mortality within 90 days. Outcome assessment was performed by one trained medical staff blinded to cortisol levels with a structured interview, if discharged, with telephone interview.

**Neuromaging**

MRI with diffusion-weighted imaging (DWI) was available in 152 stroke patients (67.2%). In those patients, DWI lesion volumes were determined by one experienced neurologist unaware of the clinical and laboratory results. The infarct volume was calculated by using the formula $0.5 \times a \times b \times c$ (where $a$ is the maximal longitudinal diameter, $b$ is the maximal transverse diameter perpendicular to $a$ and $c$ is the number of 10-mm slices containing infarct) [20].

**Blood Collection and Quantification**

Blood samples of patients and controls were obtained at 6:00 AM in the next morning of the day of admission. After centrifugation, aliquots of the samples were immediately stored at $-80^\circ$C before assay. Serum cortisol concentration was measured with a solid-phase, competitive chemiluminescent enzyme immunoassay in a calibrated IMMULITE 2000 analyzer (Diagnostic Products Corporation, Los Angeles, CA, USA). The assay was approved by the manufacturer, and had been shown to give reliable estimates of cortisol concentration in our hospital laboratory. Serum cortisol concentration was measured at $0, 6, 24, 48, 72\text{h}$ before admission. Serum cortisol concentration was measured with a solid-phase, competitive chemiluminescent enzyme immunoassay in a calibrated IMMULITE 2000 analyzer (Diagnostic Products Corporation, Los Angeles, CA, USA). The detection limit was 5 nmol/L. The intra-assay coefficient of variation (CV) and inter-assay CV were 1.5–3.2%, 2.1%–4.3%, respectively. For all measurements, levels that were not detectable were considered to have a value equal to the lower limit of detection of the assay.

**Statistical Analysis**

Results are expressed as percentages for categorical variables and as medians (interquartile ranges, IQRs) for the continuous variables. Proportions were compared using the $\chi^2$ test, and the Mann–Whitney test to compare continuous variables between groups. Correlations were determined using Spearman critical value ratings. Multivariate analysis was performed by binary logistic regression analysis, which allows adjustment for confounding factors (age, stroke syndrome, stroke etiology, the NIHSS score, infarct volume, vascular risk factors, glucose and C-reactive protein). Results were expressed as adjusted OR (odds ratios) with the corresponding 95% CIs (confidence intervals). Receiver operating characteristic (ROC) curves were utilized to evaluate the accuracy of cortisol to predict outcomes and death. Area under the curve (AUC) was calculated as measurements of the accuracy of the tests. The AUC summary equals the probability that the underlying classifier will score a randomly drawn positive sample higher than a randomly drawn negative sample. The time to death was analyzed by Kaplan–Meier survival curves. Two-sided $P$ values of less than 0.05 were regarded as significant. All statistical analysis was performed with SPSS for Windows, version 20.0 (SPSS Inc., Chicago, IL, USA).

**Results**

**Baseline characteristics of study samples**

During the inclusion period, 313 patients were registered. Acute ischemic stroke was diagnosed in 237 patients (45 with transient ischemic attack, 4 with haemorrhagic stroke, 10 with onset of symptoms >48 hours, 7 without informed consent, 4 with systemic infections, 3 with malignant tumor and 3 with surgical procedures within the last 3 weeks were not analyzed) and 226 completed follow-up (8 lost to follow-up and 3 withdrew). In the study population, 149 (65.9%) were male and median age was 65 years (interquartile ranges, IQR 53–74). The male mean time from symptom recognition to admission was 6.5 hours (IQR 5–11.5), and 198 patients (87.6%) were admitted within 24 hours of symptom recognition.
24 hours of symptom recognition. The median NIHSS score on admission was 6 points (IQR, 3 to 10). Hypercortisolemia was found in 64 (28.3%) patients. An unfavorable functional outcome was found in 77 patients (34.1%) with a median mRS score of 4 (IQR, 3–6). 34 patients died, thus the mortality rate was 15.0%.

The baseline characteristics of the 226 patients presenting with acute ischemic stroke are described in Table 1.

Serum cortisol levels and stroke characteristics

The results indicated that the serum cortisol levels were significantly (p<0.0001) higher in acutely ischemic stroke patients.

| Characteristics                             | All (n = 226) | Good outcomes (n = 149) | Poor outcomes (n = 77) | p*   |
|---------------------------------------------|---------------|-------------------------|------------------------|------|
| Male sex (%)                                | 149(65.9)     | 99(66.4)                | 50(64.9)               | NS   |
| Age (years), median (IQR)                   | 65(55–74)     | 61(50–68)               | 74(62–79)              | <0.001|
| Stroke severity, median NIHSS score (IQR)   | 6(3–10)       | 3(2–7)                  | 10(6–15)               | <0.001|
| Infarct volume (mL, IQR; n = 152)           | 9(5.8–17)     | 8(4–12)                 | 12.5(8.3–65)           | <0.001|
| Vascular risk factors no. (%)               |               |                         |                        |      |
| Hypertension                                | 169(74.8)     | 105(70.5)               | 58(83.1)               | <0.01 |
| Diabetes mellitus                           | 63(27.9)      | 40(26.8)                | 23(29.9)               | NS   |
| Hypercholesterolemia                        | 59(26.1)      | 43(28.9)                | 16(20.8)               | <0.01 |
| Coronary heart disease                      | 66(29.2)      | 44(29.5)                | 22(28.6)               | NS   |
| Atrial fibrillation                         | 49(21.9)      | 34(22.8)                | 15(19.5)               |      |
| Family history for stroke                   | 55(24.3)      | 39(26.2)                | 16(20.8)               | NS   |
| Smoking habit                               | 52(23.1)      | 36(24.2)                | 16(20.8)               |      |
| Alcohol abuse                               | 48(21.3)      | 32(21.5)                | 16(20.8)               | NS   |
| Clinical findings median (IQR)              |               |                         |                        |      |
| Systolic blood pressure (mmHg)              | 156(145–177)  | 155(143–174)            | 158(147–180)           | NS   |
| Diastolic blood pressure (mmHg)             | 90(62–99)     | 88(81–96)               | 91(84–100)             | NS   |
| Temperature (°C)                            | 36.9(36.3–37.5)| 37.0(36.4–37.5)         | 36.9(36.5–37.7)        | NS   |
| BMI (kg m^2)                                | 25.6(23.4–27.2)| 25.5(23.3–27.0)         | 25.6(23.5–27.7)        | NS   |
| Heart rate (beats min^−1)                   | 81(69–90)     | 80(69–89)               | 81(70–90)              | NS   |
| Laboratory findings median (IQR)            |               |                         |                        |      |
| Cortisol (nmol L^−1)                         | 454(389–630)  | 441(367–511)            | 643(456–786)           | <0.001|
| Total cholesterol (mmol L^−1)                | 4.11(3.41–4.94)| 4.07(3.35–4.92)         | 4.13(3.44–4.99)        | NS   |
| HDL (mmol L^−1)                              | 1.31(1.05–1.63)| 1.30(1.05–1.62)         | 1.31(1.07–1.66)        | NS   |
| LDL (mmol L^−1)                              | 2.10(1.37–2.71)| 2.11(1.38–2.71)         | 2.10(1.36–2.71)        | NS   |
| Triglycerides (mmol L^−1)                    | 1.42(1.05–1.88)| 1.37(1.06–1.72)         | 1.47(1.05–2.16)        | NS   |
| Glucose (mmol L^−1)                          | 5.62(4.99–6.93)| 5.39(4.91–6.45)         | 6.06(5.12–7.59)        | <0.01 |
| C-reactive protein (mg L^−1)                 | 4.1(3.2–8.4)  | 3.8(3.0–7.8)            | 4.4(3.5–8.9)           | <0.01 |
| Leucocyte count (×10^3 mL^−1)                | 8.4(6.2–9.7)  | 8.3(6.1–9.4)            | 8.4(6.4–9.8)           | NS   |
| Stroke syndrome no. (%)                     |               |                         |                        |      |
| TACS                                        | 27(11.9)      | 8(5.4)                  | 27(24.7)               | <0.001|
| PACS                                        | 87(38.5)      | 59(39.6)                | 87(36.4)               | NS   |
| LACS                                        | 45(19.9)      | 28(18.8)                | 17(22.1)               | NS   |
| POCs                                        | 67(29.7)      | 50(33.6)                | 17(22.1)               | <0.01 |
| Stroke etiology no. (%)                     |               |                         |                        |      |
| Small-vessel occlusive                      | 42(18.6)      | 29(19.4)                | 13(16.9)               | NS   |
| Large-vessel occlusive                      | 44(19.5)      | 30(20.1)                | 14(18.2)               | NS   |
| Cardioembolic                               | 85(37.6)      | 60(40.3)                | 25(32.3)               | NS   |
| Other                                       | 14(6.2)       | 7(4.7)                  | 7(9.1)                 | NS   |
| Unknown                                     | 41(18.1)      | 27(18.1)                | 14(18.2)               | NS   |

IQR, interquartile range; TACS, total anterior circulation syndrome; LACS, lacunar syndrome; PACS, partial anterior circulation syndrome; POCs, posterior circulation syndrome; NIHSS, National Institutes of Health Stroke Scale; BMI, Body mass index; HDL, High-density lipoproteins; LDL, Low-density lipoproteins.

*p value was assessed using Mann-Whitney U test or χ2 test.

104 patients were with good outcomes.

doi:10.1371/journal.pone.0072758.t001
as compared to normal controls (456; IQR, 397–621 nmol/L and 424; IQR, 368–515 pmol/L, respectively; Figure 1.). Cortisol levels increased with increasing severity of stroke as defined by the NIHSS score. There was a positive correlation between cortisol levels and the NIHSS score (r = 0.298, P<0.0001; Figure 2a.) There was no correlation between serum cortisol levels and age (r = 0.157, P = 0.021). There was a positive correlation between levels of cortisol and the NIHSS (r = 0.298, P<0.0001; Figure 2a.) and glucose levels (r = 0.324, P<0.0001; Figure 2b.) There was a modest correlation between levels of serum cortisol levels and age (r = 0.157, P = 0.021). There was no correlation between levels of serum cortisol levels and sex (P = 0.230). C-reactive protein and white blood cells count were not correlated with the serum cortisol levels (p = 0.103 and p = 0.124, respectively). In patients for whom MRI data were available (n = 152), there was a positive correlation between levels of cortisol and the infarct volume (r = 0.328, P<0.0001; Figure 2c.) In addition, cortisol values were significantly higher in patients with TACS 625 nmol/L (IQR 478–812) compared with patients with PACS 487 nmol/L (IQR 356–614, P<0.0001), LACS 438 nmol/L (IQR 344–613, P<0.0001) or POCS 476 nmol L (IQR 335–661, P<0.0001). Cortisol levels were not correlated with the C-reactive protein and Leucocyte count.

Serum cortisol levels and outcome

Serum cortisol levels in patients with a poor outcome were significantly greater than those in patients with a good outcome (643 [IQR, 456–786] vs 441 [IQR, 367–511] nmol/L; p<0.0001; Figure 3.). In univariate logistic regression analysis, we calculated the ORs of log-transformed cortisol levels as compared with the NIHSS score and other risk factors as presented in Table 2. With an unadjusted OR of 5.98 (95% CI, 3.63–10.52), cortisol had a strong association with functional outcome. After adjusting for all other significant outcome predictors, cortisol remained can be seen as an independent outcome predictor with an adjusted OR of 3.44 (95% CI, 2.58–6.23). In addition, age, glucose level, infarct volume, and the NIHSS score remained significant outcome predictors (Table 2).

The area under the receiver operating characteristics (ROC) curve to predict outcome for cortisol with an AUC of 0.78 (0.71–0.83) was in the range of the NIHSS with an AUC of 0.81 (0.75–0.89) (see table 3). Cortisol had a higher prognostic accuracy as compared to glucose (AUC 0.55 (0.45–0.67), P<0.01), white blood count (WBC) (AUC 0.47 (0.39–0.58), P<0.0001) and infarct volume AUC 0.69 (0.62–0.77), P<0.01. Interesting, we found that combination of cortisol and NIHSS scores could improve the NIHSS scores (AUC of the combined model, 0.87; 95% CI, 0.82–0.92; p = 0.01). This improvement was stable in an internal 5-fold cross validation that resulted in an average AUC (standard error) of 0.81 (0.036) for the NIHSS and 0.87(0.028) for the combined model, corresponding to a difference of 0.06 (0.014).

Cortisol levels in 34 patients who died were significantly greater as compared with patients who survived (682 [IQR, 511–878] vs 438 [IQR, 384–563] nmol/L; p<0.0001). After adjustment for other parameters, cortisol level remained an independent predictor for mortality with an OR of 4.21 (95% CI, 1.89–9.24; see Table 2). Receiver operating characteristic curves indicated the greatest discriminatory accuracies for cortisol level (AUC, 0.81; 95% CI, 0.73–0.89) and the NIHSS score (AUC, 0.83; 95% CI, 0.78–0.91). Combination of cortisol and NIHSS scores also could improve the NIHSS scores (AUC of the combined model, 0.90; 95% CI, 0.84–0.93; p = 0.01). Again, this improvement was stable in an internal 5-fold cross validation that resulted in an average AUC (standard error) of 0.85 (0.023) for the NIHSS and 0.90(0.027) for the combined model, corresponding to a difference of 0.05 (0.018).

The time to death was analyzed by Kaplan–Meier survival curves based on cortisol quartiles. Patients in the lowest two
quartile (cortisol <397 nmol/L and cortisol between 397 and 456 nmol/L) had a minimal risk for death, in contrast with patients with levels in the highest two quartiles (cortisol between 456 and 621 nmol/L and cortisol >621 nmol/L, respectively) (p<0.0001) (See the Figure 4.).

**Discussion**

Acute ischemic stroke acts as a stressor and thus stimulates the HPA axis resulting in increased glucocorticoid levels [4]. In this study, we firstly assessed serum cortisol levels with regard to their accuracy to predict functional outcome and mortality in patients with acute ischemic stroke within 90 days in Chinese population. Our main finding is that cortisol can be seen as an independent short-term prognostic marker of functional outcome and death in Chinese patients with acute ischemic stroke even after correcting for possible confounding factors. Combined model (cortisol and NIHSS score) can add significant additional predictive information to the clinical score of the NIHSS. We also found that that cortisol levels increased with infarct volume, neurological deficit (assessed by the NIHSS) and the clinical stroke syndrome.

These results are in accordance with the results from other studies showing that hypercortisolemia was associated with older age, greater severity of neurological deficit, larger ischemic lesions on CT, worse prognoses (a greater disability and mortality) in stroke patients [8,12,23].

Age may influence serum cortisol [24–25]. We also found a modest positive correlation between levels of serum cortisol levels and age(r = 0.157, P = 0.021). Previous studies reported that fasting glucose level and insulin resistance increased with higher cortisol level [6–7]. We also found that there was a positive correlation between levels of cortisol and glucose levels (r = 0.324, P<0.0001; Figure 3.). As expected, high levels of cortisol were associated with diabetes mellitus. The association may be confounded by obesity. It has been reported that cortisol correleated positively to inflammatory response after stroke, and it was suggested that cytokines modulate the cortisol response after acute stroke [11] by stimulating the HPA axis leading to increased levels of cortisol in the periphery [26]. Our findings were inconsistent with previous findings, and we did not find correlation between inflammatory response and serum cortisol levels.

In our study, we found hypercortisolemia in 28.3% of patients with acute stroke. The frequency of hypercortisolemia in stroke patients has been reported in the range of 24%–38% [8,12,27]. This is very interesting because despite using different methods of assessment and the study population are not the same, a similar

---

**Figure 2. Correlation between serum cortisol levels and others predictors.** (a) Correlation between the National Institutes of Health Stroke Scale (NIHSS) and serum cortisol levels. (b) Correlation between the serum glucose and cortisol levels. (c) Correlation between the infract volume and serum cortisol levels.

doi:10.1371/journal.pone.0072758.g002
prevalence of hypercortisolemia was obtained, indicating a similar increase in adrenocortical output in stroke.

Whether the high serum cortisol is just an epiphenomenon to stroke severity or independently contributes to prognosis remains uncertain. A severe stroke *per se* implicates a poor outcome. However, there are several other reasons explaining unfavorable outcome in patients with higher cortisol levels. It cannot be excluded that these HPA axis-related hormones, once released, secondarily reinforce damage of hypoxic brain tissue and thereby contribute to the poor outcomes. Firstly, increased exposure to

![Figure 3. Serum cortisol levels in acute ischemic stroke patients with good and poor outcomes.](image)

**Figure 3. Serum cortisol levels in acute ischemic stroke patients with good and poor outcomes.** Mann–Whitney U-test. All data are interquartile ranges (IQR). Significantly higher in poor as compared to good group (P<0.0001).
doi:10.1371/journal.pone.0072758.g003

### Table 2. Univariate and multivariate Analysis.

| Parameter                                      | Univariate Analysis | Multivariate Analysis |
|------------------------------------------------|---------------------|-----------------------|
|                                                | ORa 95% CIa  | P  | ORa 95% CIa  | P  |
| **Predictor: functional outcome**             |                 |    |                 |    |
| Cortisol (increase per log unit)b              | 5.98  3.63–10.52 | <0.0001  | 3.44  2.58–6.23 | <0.0001  |
| Age (increase per unit)                        | 1.36  0.85–2.18 | 0.031  | 1.54  0.83–2.89 | 0.012  |
| NIHSS (increase per unit)                      | 1.23  1.06–1.45 | <0.0001  | 1.30  1.14–1.47 | <0.0001  |
| Glucose (increase per unit)                    | 1.19  1.04–1.36 | 0.012  | 1.10  0.92–1.31 | 0.030  |
| CRP (increase per unit)                        | 1.23  1.06–1.45 | 0.008  | 1.16  1.11–1.23 | 0.021  |
| Infarct volume (increase per unit)             | 1.11  1.00–1.22 | 0.006  | 1.13  0.87–1.31  | 0.002  |
| **Predictor: death**                           |                 |    |                 |    |
| Cortisol (increase per log unit)b              | 10.32  5.68–18.45 | <0.0001  | 4.21  1.89–9.24 | <0.0001  |
| Age (increase per unit)                        | 1.42  0.99–1.87 | 0.023  | 1.34  1.08–1.99 | 0.043  |
| NIHSS (increase per unit)                      | 1.52  1.14–2.99 | <0.0001  | 1.42  0.95–2.07 | 0.027  |
| Glucose (increase per unit)                    | 1.33  1.12–1.68 | 0.003  | 1.33  0.88–2.07 | <0.0001  |
| CRP (increase per unit)                        | 1.29  1.08–1.65 | 0.011  | 1.12  0.98–1.56 | 0.016  |
| Infarct volume (increase per unit)             | 1.19  1.02–1.54 | 0.007  | 1.06  1.04–1.09 | <0.0001  |

*Note that the odds ratio corresponds to a unit increase in the explanatory variable.

bThis corresponds to an increase per unit of the log transformation of cortisol (thus, a log-transformed increase of 1 corresponds to a cortisol increase of 10 nmol/L).

OR, odds ratio; CI, confidence interval; CRP, C-reactive protein; NIHSS, National Institutes of Health Stroke Scale.
doi:10.1371/journal.pone.0072758.t002
Cortisol contributes to increased fat accumulation in visceral depots [28]. Hypercortisolism itself may potentiate ischemic neuronal injury, especially in hippocampal neurons [29–30], and the corticosterone-synthesis inhibitor, metyrapone, was able to prevent ischemia-induced loss of synaptic function in the hippocampus of rats [31]. The hippocampus has an important role in the feedback regulation of the HPA axis. Dysfunction of hippocampal might result in false HPA axis feedback, which increase cortisol and causes a vicious circle [32]. Secondly, patients with stroke and high cortisol levels are more prone to suffer from adverse cardiac events, which may lead to higher mortality rates [32–33]. Finally, a bad prognosis after stroke is the development of infectious disease which is related to an immune dysregulation resulting from neuroendocrine disturbance after stroke [34]. High cortisol levels are more susceptible to infections [7]. The specific mechanism needs to be further studied in population-based larger cohort studies.

Some limitations of this observational study merit consideration. First, without serial measurement of the circulating cortisol levels, this study yielded no data regarding when and how long cortisol is elevated in these patients. Second, the effects of circulating cortisol on long-term clinical outcome were not included in the study protocol, so these relationships were not examined beyond the 90-day clinical outcome. Third, we assessed all-cause mortality because classification of death in clinical practice can sometimes be difficult and unreliable [35]. Forth, this was only a preliminary study; these results need to be replicated in more prospective studies to determine whether or not they are stable and valid.
our findings are confirmed, clinicians assessing patients with acute stroke should consider measuring serum levels of cortisol routinely on admission.

Conclusions

Despite its inherent limitations, our study suggested that cortisol levels may reliably predict short-term prognosis at its onset in Chinese patient with acute ischemic stroke. Combined model (cortisol and NIHSS score) can add significant additional predictive information to the clinical score of the NIHSS. We recommend that further studies should be carried out with respect to the mechanism between increased cortisol levels and poor outcome. If it is possible to elucidate this, the prognosis of these stroke patients might be improved.

Acknowledgments

We are grateful to the Department of Neurology; the nurses, physicians, and patients who participated in our study, and the staff of the central laboratory of the Hospital. Both authors have contributed significantly, and both authors are in agreement with the content of the manuscript.

Author Contributions

Conceived and designed the experiments: JS WJZ. Performed the experiments: JS WJZ. Analyzed the data: WJZ. Contributed reagents/materials/analysis tools: JS WJZ. Wrote the paper: JS.

References

1. Liu L, Wang D, Wong KS, Wang Y (2011) Stroke and stroke care in China: huge burden, significant workload, and a national priority. Stroke 42:3651–3654.
2. Johnston SC, Mendis S, Mathers CD (2009) Global variation in stroke burden and mortality: estimates from monitoring, surveillance, and modeling. Lancet Neurol; 8:345–354
3. McEwen BS (2007) Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev 87: 973–994.
4. Fassbender K, Schmidt R, Mosner R, Daffertshofer M, Hennerici M (1994) Pattern of activation of the hypothalamic–pituitary–adrenal axis in acute stroke. Relation to acute confusional state, extent of brain damage, and clinical outcome. Stroke 25:1105–1108.
5. Fiorenino L, Saxbe D, Alesi CA, Woods DI, Martin JL (2012) Diurnal cortisol and functional outcomes in post–acute rehabilitation patients. J Gerontol A Biol Sci Med Sci 67: 677–682.
6. O’Neill PA, Davies L, Fullerton KJ, Bennett D (1991) Stress hormone and blood glucose response following acute stroke in the elderly. Stroke 22:842–847.
7. Schooler LM, Peeters GM, van Schoor NM, Lips P (2009) Relationships between cortisol level, mental stress and chronic diseases in older persons. Clin Endocrinol (Oxf) 71:779–786.
8. Olson T, Marklund N, Gustafson Y, Nisman B (1992) Abnormalities at different levels of the hypothalamic–pituitary–adrenocortical axis early after stroke. Stroke 23:1573–1576.
9. Zetterling M, Engstroem BE, Hallberg L, Hillelof L, Enblad P, et al (2011) Cortisol and adrenocorticotrophic hormone dynamics in the acute phase of subarachnoid haemorrhage. Br J Neurosurg 25:684–692.
10. Fehel JH, Hardy PM, Campell RG, Goldstein MN, Jurett R (1977) Prognostic value of the stress response following stroke. JAMA 238:1374–1376.
11. Christensen H, Boysen G, Johannesen HH (2004) Serum-cortisol reflects severity and mortality in acute stroke. J Neurol Sci 217: 175–180.
12. Slowik A, Turaj W, Pankiewicz J, Dziedzic T, Szermer P (2002) Hypercortisolism in acute ischemic stroke: effects of acute phase disturbances on long-term mortality. J Neurol Sci 217: 27–32.
13. Anne M, Juha K, Timo M, Mikko T, Ohli V (2007) Neuroendocrine activation in ischemic stroke: effects of acute phases on the NIH stroke scale score: a clinical examination scale. Stroke 2006:470–476.
14. Hatanan S (1976) Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ 54:541–543.
15. Brott T, Adams HP Jr, Olinger CP, Barsan W G, et al (1989) Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24: 35–41
16. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24: 35–41
17. Banford J, Sanderscock P, Dennis M, Burn J, Warlow C (1991) Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 337:1521–1526.
18. Bhatt R, Bagchi R (1988) Recovery of motor function after stroke. Stroke 19:1497–1500.
19. Sims JR, Gharai LR, Schaefer PW, Vangel M, Rosenthal ES (2009) ABC/2 for rapid clinical estimate of infarct, perfusion, and mismatch volumes. Neurology 72: 2104–2110
20. Birmaher OG, Sinanovic O, Cakicne A, Smajlovic D (2005) Ischemic stroke as reaction to an acute stressful event Med Arh 59:79–82.
21. Mu DL, Wang DX, Li LH, Shan GJ, Li J (2010) High serum cortisol level is associated with increased risk of delirium after coronary artery bypass graft surgery: a prospective cohort study. Crit Care 14:R230.
22. Murrow K, Fogelholm R, Kettunen S, Vuorela AL (1993) Serum cortisol and outcome of ischemic brain infarction. J Neurol Sci 116:12–17.
23. Parker CR Jr, Slayden SM, Azizz R, Crabbe SL, Hines GA (2000) Effects of aging on adrenal function in the human: responsiveness and sensitivity of adrenal androgens and cortisol to adrenocorticotropin in premenopausal and postmenopausal women. J Clin Endocrinol Metab 85: 48–54.
24. Wilkinson CW, Perrie EC, Murray SR, Colasurdo EA, Raskind MA (2001) Human glucocorticoid feedback inhibition is reduced in older individuals: evening study. J Clin Endocrinol Metab 86: 545–550.
25. Chrousos GP (1995) The hypothalamic–pituitary–adrenal axis and immune mediated inflammation. N Engl J Med 332: 1351–1362.
26. Aström M, Olsson T, Axlund K (1995) Different linkage of major depression to hypothalamic-pituitary-adrenocortical function and clinical outcome after ischemic stroke. Expert Rev Neurother 1:225–239.
27. Cunha RL, Salles P, Carvalho F, da Silva Netto RV, Machado V, et al (2011) Glucocorticoid receptor expression in rat hippocampus is related to inflammatory response. J Neuroinflammation 8:79.
28. Anagnostis P, Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP (2009) The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab 94: 2692–2701.
29. Potocki M, Breidthardt T, Mueller A (2010) Copeptin and risk stratification in patients with acute dyspnea. Critical Care 14: R213.